Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer

Tomasz M. Beer, Eugene D. Kwon, Charles G. Drake, +20

Journal of Clinical Oncology

PharmacotherapyImmunotherapeuticsImmunotherapyMinimally Symptomatic PatientsPhase Iii Trial +14

Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial

Padmanee Sharma, Margaret K. Callahan, Petri Bono, +15

The Lancet Oncology

UrologyGenitourinary CancerMedicineCheckmate 032Immune Checkpoint Inhibitor +5

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

Yelena Y. Janjigian, Johanna C. Bendell, Emiliano Calvo, +12

Journal of Clinical Oncology

Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients

Niels Halama, Inka Zoernig, Anna Berthel, +23

Cancer Cell

Cancer ImmunosurveillanceAnti-ccr5 TherapyMedicineImmunologyTumor Immunity +8

Localization and Density of Immune Cells in the Invasive Margin of Human Colorectal Cancer Liver Metastases Are Prognostic for Response to Chemotherapy

Niels Halama, Sara Michel, Matthias Kloor, +16

Cancer Research

ImmunologyPathologyHigh DensitiesImmunotherapyTil Densities +14

Surgery for Recurrent Pancreatic Ductal Adenocarcinoma

Jörg Kleeff, Carolin Reiser, Ulf Hinz, +5

Annals of Surgery

A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors

Mariano J. Alvarez, Prem S. Subramaniam, Laura H. Tang, +55

Nature Genetics

GliomaMedicinePharmacologyNeuroendocrine DisorderPharmacotherapy +8

Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma

Andreas Bonertz, Jürgen Weitz, Dong-Ho Kim Pietsch, +12

Journal of Clinical Investigation

Healthy SubjectsT-regulatory CellImmunologyTreg DepletionPathology +19

Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer

Salah‐Eddin Al‐Batran, Akin Atmaca, Susanna Hegewisch‐Becker, +8

Journal of Clinical Oncology

Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC).

Naiyer A. Rizvi, Julie R. Brahmer, Sai‐Hong Ignatius Ou, +17

Journal of Clinical Oncology

Pd-l1 ExpressionMedicineImmunologyTumor ImmunityPathology +11